Lindus

Lindus Therapeutics in-licenses clinical-stage assets and develops them through its integrated clinical development platform. The platform includes Citrus, an AI-native trial operating system, and SOURCE, an AI system for evaluating drug assets, covering feasibility, patient identification, screening and trial oversight.

The company collaborates with biotech and pharma companies and also in-licenses and develops therapeutic assets itself, aiming to take programs further after value inflection points or approval. It describes itself as originally founded as a technology-first clinical research organization. The revenue model is not stated in the input.

The website reports 45 completed clinical trials, a full-time team of over 80, and a footprint across North America and Western Europe. Co-founders include Meri Beckwith (CEO) and Michael Young. Open roles include a Full Stack Engineer in London, a Clinical Systems Engineer (US and London), and senior director roles in biostatistics and clinical operations in the US. The founding year is not stated.

Product: Citrus AI-native clinical trial operating system and SOURCE AI asset-identification system, used within an integrated clinical development platform.